Bristol-Myers Squibb Company BMY
Set alert
As of Nov 2, 11:41 AM ET
- YTD
- +15.83%
- 1 year
- +35.62%
- Open
- 62.45
- Prev close
- 62.48
- Mkt cap
- 127.60B
- Vol
- 3.53M
- Avg vol
- 11.50M
- EPS
- 4.51
- P/E
- 13.84
- Div yield
- 4.10%
More statistics
- Low
- 62.17
- High
- 62.84
- Forward P/E
- 9.45
- Beta
- 0.00
- Short ratio
- 3.50
- Inst. own
- 84.93%
- Dividend
- 2.52
- Ex-div date
- Oct 1, 2026
- Earnings
- Feb 4, 2027
- 50-d avg
- 62.86
- 200-d avg
- 59.92
- 1y target
- 65.39
5D chart
Events in this range
- Oct 29, 2026Earnings: 1.35; estimate 1.1; surprise 22.73%
- Oct 30, 2026Rating: Morgan Stanley · Underweight → Underweight
Signals (111)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 11:30 AM | 11 minutes ago |
| MACD: Sell Signal | Nov 2, 11:30 AM | 11 minutes ago |
| SMA: Bullish | Nov 2, 11:25 AM | 16 minutes ago |
| SMA: Bearish | Nov 2, 11:15 AM | 26 minutes ago |
| SMA: Bearish | Nov 2, 11:10 AM | 31 minutes ago |
| SMA: Bullish | Nov 2, 10:35 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 10:35 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 10:30 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 10:20 AM | 1 hour ago |
| MACD: Buy Signal | Nov 2, 10:20 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 10:00 AM | 1 hour ago |
| SMA: Bullish | Nov 2, 9:55 AM | 1 hour ago |
| RSI: Oversold | Nov 2, 9:30 AM | 2 hours ago |
| SMA: Bearish | Oct 30, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:45 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:35 PM | 5 days ago |
| RSI: Oversold | Oct 28, 12:10 PM | 5 days ago |
| RSI: Oversold | Oct 28, 12:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 6 days ago |
News
1 hour ago zacks.com
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.
2 days ago seekingalpha.com
Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)
Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic ahead of looming patent cliffs. BMY's Growth Portfolio now comprises ~59% of revenues, with 8 medicines…
-
2 days ago benzinga.com
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.
3 days ago zacks.com
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
BMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.
3 days ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
3 days ago marketbeat.com
Bristol Myers Squibb Q3 Earnings Call Highlights
Bristol Myers Squibb NYSE: BMY raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a…
3 days ago fool.com
Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Bristol Myers Squibb's Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company's 7% revenue gain to $13.1 billion. Adjusted EPS fell 17% to…
3 days ago benzinga.com
Bristol-Myers Squibb Says AI Is Already Speeding Up Drug Research — And It's Measuring The Impact
Bristol-Myers beats Q3 2026 estimates with $13.07B in revenue and raises full-year sales guidance driven by newer drug growth.
3 days ago zacks.com
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
4 days ago seekingalpha.com
Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
4 days ago zacks.com
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
4 days ago zacks.com
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.63 per share a year ago.
4 days ago benzinga.com
Bristol-Myers Squibb Q3 2026 Earnings Call Transcript
Bristol-Myers Squibb (NYSE:BMY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
4 days ago wsj.com
Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises
Bristol Myers Squibb raised its full-year revenue outlook due to higher third-quarter revenue.
-
4 days ago benzinga.com
Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est
Bristol-Myers Squibb (NYSE:BMY) lowers FY2026 Adj EPS guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 analyst estimate. Raises FY2026 sales outlook from $49.000 billion-$50.000 billion to $49.750…
-
4 days ago benzinga.com
Bristol-Myers Squibb Q3 Adj. EPS $1.35 Beats $1.17 Estimate, Sales $13.069B Beat $12.738B Estimate
Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.17 by 15.38 percent. This is a 17.18 percent decrease over earnings of…
4 days ago businesswire.com
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2026.
4 days ago benzinga.com
Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings
Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
4 days ago benzinga.com
Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test
Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
5 days ago fool.com
3 Magnificent Dividend Stocks for Risk-Averse Investors
Every investment carries some measure of risk. These pose less risk than others that offer similar rewards.
6 days ago zacks.com
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
6 days ago defenseworld.net
8,656 Bristol Myers Squibb Company $BMY Shares Sold by Evergreen Capital Management LLC
Evergreen Capital Management LLC reduced its stake in Bristol Myers Squibb Company (NYSE: BMY) by 20.3% during the undefined quarter, according to the company in its most recent filing with the SEC.…
6 days ago fool.com
Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters
It also demonstrated very promising results when evaluated in other solid tumors. The company's involvement in the program is part of a broader effort to develop its burgeoning growth portfolio.
6 days ago zacks.com
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Bristol-Myers Squibb heads into Q3 earnings with growth drugs and higher Eliquis guidance offsetting legacy portfolio declines.
6 days ago fool.com
3 Cheap Dividend Stocks I'd Buy Without Any Hesitation
Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.
6 days ago marketbeat.com
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Bristol Myers Squibb TodayBMYBristol Myers Squibb$61.20 -0.28 (-0.45%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$42.52▼$68.64Dividend…
6 days ago fool.com
Bristol Myers Squibb: Bargain Buy or Value Trap?
The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.
1 week ago 247wallst.com
3 Blue-Chip Dividend Stocks That Show Why Roth IRA Income Can Be Worth More
Where you hold a dividend stock matters almost as much as which one you pick, and three blue-chip payers reveal exactly how much the IRS quietly collects each year depending on your account type.
1 week ago zacks.com
Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Bristol Myers (BMY) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates…
-
1 week ago benzinga.com
Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78
Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.
1 week ago fool.com
Breakfast News: Science Strikes Back at Cancer
Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
-
1 week ago benzinga.com
Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC
Late-breaking results to be presented in an oral presentation at ESMO 2026PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this…
1 week ago benzinga.com
What's Going On with Bristol Myers Squibb Stock on Friday?
Bristol Myers Squibb releases trial results for their multiple sclerosis CAR T therapy and Phase 3 breast cancer conjugate candidate.
-
1 week ago benzinga.com
Bristol Myers Squibb Presents Interim Safety, Efficacy Data From Its Multiple Sclerosis Groups Of Phase 1 Trial Of Zolacabtagene Autoleucel At MSToronto 2026
Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2…
-
1 week ago benzinga.com
Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio
Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected…
-
1 week ago benzinga.com
SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026
Late-breaking results to be presented in an oral presentation at ESMO 2026With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine…
-
2 weeks ago benzinga.com
BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer
Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in…
2 weeks ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 weeks ago benzinga.com
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60
Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $65 to $60.
2 weeks ago benzinga.com
Why Is Contineum Therapeutics Stock Falling Monday?
BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.
3 weeks ago benzinga.com
Why Is Bristol Myers Squibb Stock Gaining Monday?
Bristol Myers Squibb stock jumped over 4% after positive Phase 3 results for neuroendocrine tumors and pulmonary fibrosis treatments.
-
3 weeks ago benzinga.com
Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile
Bristol Myers Squibb (NYSE:BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb…
-
3 weeks ago benzinga.com
Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial
In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with…
3 weeks ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 weeks ago benzinga.com
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.
-
3 weeks ago benzinga.com
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53
Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.
3 weeks ago benzinga.com
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
-
3 weeks ago benzinga.com
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.
-
4 weeks ago benzinga.com
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59
Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.
-
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…